Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

Role of CMV chemokine receptor M33 in airway graft rejection in a mouse transplant model

HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs.

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

A Novel MyD88 Inhibitor Attenuates Allograft Rejection after Heterotopic Tracheal Transplantation in Mice

Allograft Rejection-Related Gene Expression in the Endothelial Cells of Renal Transplantation Recipients after Cytomegalovirus Infection

High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function

CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation.

The Impact of Pretransplant Cytomegalovirus Infection on Acute Renal Allograft Rejection

NKG2C Natural Killer Cells in Bronchoalveolar Lavage Are Associated With Cytomegalovirus Viremia and Poor Outcomes in Lung Allograft Recipients

Mir-199B-5p Regulates Immune-Mediated Allograft Rejection after Lung Transplantation Through the GSK3β and NF-κB Pathways

Expression of Regulatory T Cells and Related Cytokines in Mice Allogenic Corneal Transplantation Rejection

Role of cytomegalovirus infection in renal allograft rejection: study of a possible mechanism

The Immunopathology of Pulmonary Rejection after Murine Lung Transplantation

MCMV Dissemination from Latently-Infected Allografts Following Transplantation into Pre-Tolerized Recipients

Cxcl10 and Cxcl13 Expression Were Highly Up-Regulated in Peripheral Blood Mononuclear Cells in Acute Rejection and Poor Response to Anti-Rejection Therapy

Deletion of Smad3 Improves Cardiac Allograft Rejection in Mice.

Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter study

A decline in club cell secretory proteins in lung transplantation is associated with release of natural killer cells exosomes leading to chronic rejection

Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword

Association between cytomegalovirus viremia and long-term outcomes in lung transplant recipients